Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply.

Mahadevan, U; Vermeire, S; Lasch, K; Abhyankar, B; Bhayat, F; Blake, A; Dubinsky, M

Mahadevan, U; Vermeire, S; Lasch, K; Abhyankar, B; Bhayat, F; Blake, A; Dubinsky, M.

Affiliation

Mahadevan U; Center for Colitis and Crohn's Disease, University of California San Francisco, San Francisco, CA, USA.
Vermeire S; University Hospital Gasthuisberg, Leuven, Belgium.
Lasch K; Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
Abhyankar B; Formerly of Takeda Development Centre Europe Ltd, London, UK.
Bhayat F; Takeda Pharmaceuticals USA, Inc., Deerfield, IL, USA.
Blake A; Takeda Development Centre Europe Ltd, London, UK.
Dubinsky M; Department of Pediatrics, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Aliment Pharmacol Ther ; 48(3): 388-389, 2018 08.

Article in En | MEDLINE | ID: mdl-29998501

Subject(s)

Inflammatory Bowel Diseases; Antibodies, Monoclonal, Humanized; Female; Humans; Pregnancy

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Inflammatory Bowel Diseases Limits: Female / Humans / Pregnancy Language: En Journal: Aliment Pharmacol Ther Journal subject: FARMACOLOGIA / GASTROENTEROLOGIA / TERAPIA POR MEDICAMENTOS Year: 2018 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google